Richard A. Miller MD - 31 Mar 2023 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Role
President and CEO, Director
Signature
/s/ Leiv Lea, as Attorney-in-Fact for Richard A. Miller
Issuer symbol
CRVS
Transactions as of
31 Mar 2023
Net transactions value
$0
Form type
4
Filing time
03 Apr 2023, 16:30:37 UTC
Previous filing
16 Dec 2022
Next filing
14 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRVS Stock Option (Right to Buy) Award $0 +800,000 $0.000000 800,000 31 Mar 2023 Common Stock 800,000 $0.9100 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from March 31, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.